

Acknowledgements

The authors thank Mr. C.W.P. Reynolds for his careful linguistic help with this manuscript. The authors declare no competing financial interests.

Author details

¹Department of Pediatrics, Yokohama City University, 3-9 Fukuura, Kanazawaku, Yokohama 236-0004, Japan. ²Department of Pathology, Yokohama City University, 3-9 Fukuura, Kanazawaku, Yokohama 236-0004, Japan.

Authors' contributions

TM drafted the manuscript and participated in its design. SF, RO, and TI participated in drafting of the manuscript and participated in its design. YI participated in the drafting of the manuscript and supplied the pathological image used for the manuscript. SY conceived of the case report, participated in drafting the manuscript and gave final approval for the version to be submitted for publication.

Competing interests

The authors declare that they have no competing interests.

Received: 5 March 2009

Accepted: 4 February 2010 Published: 4 February 2010

References

1. Cassidy JT, Lindsley CB: **Juvenile Dermatomyositis**. *Textbook of Pediatric Rheumatology* Philadelphia: Elsevier Saunders; Cassidy JT, Petty RE, 5 2005, 407-41.
2. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, MacNeil I, Momy JA, Avery G, Feldman BM: **Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis**. *Arthritis Rheum* 2000, **43**:541-9.
3. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP: **Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis**. *J Am Acad Dermatol* 2002, **47**:505-11.
4. Mukamel M, Horev G, Mimouni M: **New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment**. *J Pediatr* 2001, **138**:763-6.
5. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH: **TNF α -308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α , disease duration, and pathologic calcifications**. *Arthritis Rheum* 2000, **43**:2368-77.
6. Pachman LM, Abbott K, Sinacore JM, Amoroso L, Dyer A, Lipton R, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray L, Ramsey-Goldman R: **Duration of illness is an important variable for untreated children with juvenile dermatomyositis**. *J Pediatr* 2006, **148**:247-53.
7. Riley P, MacCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA: **Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis**. *Rheumatology* 2008, **47**:877-80.
8. Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, Yamazaki T: **Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease**. *Inflamm Bowel Dis* 2008, **14**:396-400.
9. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Rojas-Rodriguez J, Escobar LE: **Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis**. *Joint Bone Spine* 2007, **74**:500-3.
10. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I: **Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells**. *Immunopharmacology* 1998, **40**:11-20.
11. Calabrese L, Fleischer AB: **Thalidomide: current and potential clinical applications**. *Am J Med* 2000, **108**:487-95.
12. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, Giczewski D, Webb C, Spevak L, Boskey AL: **Composition of Calcifications in children with juvenile dermatomyositis association with chronic cutaneous inflammation**. *Arthritis Rheum* 2006, **54**:3345-3350.
13. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: **Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes**. *J Exp Med* 1991, **173**:699-703.

14. Gordon JN, Goggin PM: **Thalidomide and its derivatives: emerging from the wilderness**. *Postgrad Med J* 2003, **79**:127-32.
15. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: **VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation**. *Nat Med* 1999, **5**:617-8.
16. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC, Lindner DJ: **IFN- α 2b and thalidomide synergistically inhibit tumor-induced angiogenesis**. *J Interferon Cytokine Res* 2003, **23**:3-10.
17. Raje N, Anderson KC: **Thalidomide and immunomodulatory drugs as cancer therapy**. *Curr Opin Oncol* 2002, **14**:635-40.
18. Meierhofer C, Dünzendorfer S, Wiedermann CJ: **Theoretical basis for the activity of thalidomide**. *Biodrugs* 2001, **15**:681-703.

doi:10.1186/1546-0096-8-6

Cite this article as: Miyamae et al.: Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. *Pediatric Rheumatology* 2010 **8**:6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



